Therapeutic markings applied to tissue

• US 20040253281A1
• Filed: 06/12/2003
• Published: 12/16/2004
• Est. Priority Date: 06/12/2003
• Status: Abandoned Application

• Current Assignee: Atrium Medical Corporation (Getinge AB)
• Original Assignee: Atrium Medical Corporation (Getinge AB)
• Inventors: Martakos, Paul, Labrecque, Roger, Herweck, Steve A., Moodie, Geoffrey
• Application Number:
  US10/461,146
• Publication Number:
  US 20040253281A1
• Time in Patent Office: Days
• US Class Current: 424/401
• CPC Class Codes: A61K 47/02 Inorganic compounds
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 47/38 Cellulose; Derivatives thereof
• CPC Class Codes: A61L 27/50 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: A61L 29/14 Materials characterised by their function or physical properties , e.g. lubricating compositions
• CPC Class Codes: A61L 29/18 Materials at least partially X-ray or laser opaque
• CPC Class Codes: A61L 31/14 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: A61L 31/18 Materials at least partially X-ray or laser opaque

Abstract

A medical ink is loaded with a number of therapeutic agents. The ink is then applied directly to the tissue of a patient, either internally or externally, resulting in a therapeutic ink marking. The therapeutic ink marking can include surface activation of an immobilizing medication, controlled medication release, and/or the ability to use dyes or pigments to delineate different active ingredients by location and dosage. The active medicinal compounds can be placed on selective areas of the tissue as applied in the marking. The marking can provide a detectable and dosemetric controllable delivery to a specific targeted and localized location to provide the maximum therapeutic benefit. The medicated ink may be applied to a number of different methods. Dimensions of the markings can further serve to control and identify to the user the dosage amount of the medical agent applied to the tissue. Multiple types of medical agents with multiple application methods can be used. The medicated ink can be dyed, pigmented, or used as a colorless vehicle, and can be formulated to incorporate either immobilized or exuding active agents onto the tissue.

Claims

1. A therapeutic ink for forming a therapeutic marking on tissue of a patient, the therapeutic ink comprising:

a component providing an indication of location of the ink when applied to the tissue; and

at least one therapeutic agent component for creating a therapeutic effect when the therapeutic ink is applied to the tissue.

2. The therapeutic ink of claim 1, wherein the marking is applied with a marker.

3. The therapeutic ink of claim 1, wherein a dosage of the medical agent in the therapeutic ink can be determined by inspection of the marking.

4. The therapeutic ink of claim 1, wherein a dosage of the at least one therapeutic agent in the therapeutic ink is controlled by detectable dimensions of the marking on the tissue.

5. The therapeutic ink of claim 1, wherein a dosage of the at least one therapeutic agent in the therapeutic ink is determinable by visual detection of the marking.

6. The therapeutic ink of claim 1, wherein the at least one therapeutic ink comprises two or more therapeutic inks forming the marking and wherein the marking comprises a first color and a second color that differs from the first color.

7. The therapeutic ink of claim 1, wherein the marking comprises more than one type of therapeutic agent.

8. The therapeutic ink of claim 1, wherein the therapeutic agent comprises a diagnostic medical agent.

9. The therapeutic ink of claim 1, wherein the marking is permanently applied to the tissue.

10. The therapeutic ink of claim 1, wherein the marking is temporarily applied to the tissue.

11. The therapeutic ink of claim 1, wherein the therapeutic agent comprises an antioxidant agent.

12. The therapeutic ink of claim 1, wherein the therapeutic agent comprises an antihypertensive agent.

13. The therapeutic ink of claim 1, wherein the therapeutic agent comprises an anti-inflammatory agent.

14. The therapeutic ink of claim 1, wherein the therapeutic agent comprises a growth factor antagonist.

15. The therapeutic ink of claim 1, wherein the therapeutic agent comprises an antiplatelet agent.

16. The therapeutic ink of claim 1, wherein the therapeutic agent comprises an anticoagulant agent.

17. The therapeutic ink of claim 1, wherein the therapeutic agent comprises a thrombolytic agent.

18. The therapeutic ink of claim 1, wherein the therapeutic agent comprises drugs to alter lipid metabolism.

19. The therapeutic ink of claim 1, wherein the therapeutic agent comprises an ACE inhibitor.

20. The therapeutic ink of claim 1, wherein the therapeutic agent comprises at least one of an antiproliferative and an antineoplastic.

21. The therapeutic ink of claim 1, wherein the therapeutic agent comprises a tissue growth stimulant.

22. The therapeutic ink of claim 1, wherein the therapeutic agent comprises a chemical donor of at least one of Nitric oxide and Super Oxygenated 02.

23. The therapeutic ink of claim 1, wherein the therapeutic agent comprises promotion of hollow organ occlusion or thrombosis agents.

24. The therapeutic ink of claim 1, wherein the therapeutic agent comprises a functional protein and factor delivery agent.

25. The therapeutic ink of claim 1, wherein the therapeutic agent comprises a second messenger targeting agent.

26. The therapeutic ink of claim 1, wherein the therapeutic agent comprises an angiogenic agent.

27. The therapeutic ink of claim 1, wherein the therapeutic agent comprises an anti-angiogenic agent.

28. The therapeutic ink of claim 1, wherein the therapeutic agent comprises an inhibition of protein synthesis agent.

29. The therapeutic ink of claim 1, wherein the therapeutic agent comprises an anti-infective agent.

30. The therapeutic ink of claim 1, wherein the therapeutic agent comprises a gene delivery agent.

31. The therapeutic ink of claim 1, wherein the therapeutic agent comprises at least one of a tissue perfusion enhancer and a tissue absorption enhancer.

32. The therapeutic ink of claim 1, wherein the therapeutic agent comprises a nitric oxide donative derivative.

33. The therapeutic ink of claim 1, wherein the therapeutic agent comprises drug carrying nano-particles.

34. The therapeutic ink of claim 1, wherein the therapeutic agent comprises drug carrying micro-spheres.

35. The therapeutic ink of claim 1, wherein the therapeutic agent comprises at least one of an imaging agent and a contrast agent.

36. The therapeutic ink of claim 1, wherein the therapeutic agent comprises an anesthetic agent.

37. The therapeutic ink of claim 1, wherein the therapeutic agent comprises a descaling agent.

38. The therapeutic ink of claim 1, wherein the therapeutic agent comprises a cheomotherapeutic agent.

39. The therapeutic ink of claim 1, wherein the therapeutic agent is suitable for release into the body of the patient.

40. The therapeutic ink of claim 1, wherein the therapeutic agent is suitable for release into the tissue of the patient.

41. The therapeutic ink of claim 1, wherein the therapeutic agent includes an immobilized drug.

42. The therapeutic ink of claim 1, wherein the therapeutic agent exudes from the marking.

43. The therapeutic ink of claim 1, wherein the therapeutic agent is enclosed in liposomes.

44. The therapeutic ink of claim 1, wherein the ink marking is visible to the human eye without visual aid.

45. The therapeutic ink of claim 1, wherein the ink marking is visible to the human eye with use of a visual aid.

46. The therapeutic ink of claim 1, wherein the manner in which the ink marking is applied comprises at least one of a color code format, a shape format, a symbol format, and a size format to convey information.

47. The therapeutic ink of claim 1, wherein the manner in which the ink marking is applied comprises application of the ink marking to indicate at least one of drug type, drug brand, drug dosage, dimensions, sizing, placement, orientation, and trimming guidelines.

48. A method of applying a detectable therapeutic information conveying marking to tissue of a patient, comprising the steps of:

providing an applicator holding detectable therapeutic ink; and

applying a first marking of the detectable therapeutic ink to the tissue to apply a specific dosage of at least one therapeutic agent, wherein the dosage is controlled by the quantity of the first marking.

49. The method of claim 48, further comprising pre-treating the tissue prior to applying the first marking.

50. The method of claim 48, further comprising applying a second marking detectably different from the first marking.

51. The method of claim 48, wherein applying the first marking comprises applying multiple therapeutic agents to the tissue.

52. The method of claim 48, wherein at least the first marking is applied to the tissue by a marker pen.

53. The method of claim 48, wherein at least the first marking is applied to the tissue by a stamp device.

54. The method of claim 48, wherein at least the first marking is applied to the tissue in the form of a tattoo.

55. The method of claim 48, wherein the first marking comprises a first color.

56. The method of claim 55, further comprising a second marking formed of a second color that is visually differentiable from the first color.

57. The method of claim 48, wherein the therapeutic ink is suitable for release into the body of the patient.

58. The method of claim 48, wherein the therapeutic ink is suitable for release into the tissue of the patient.

59. A method of applying a therapeutic agent to tissue of a patient, comprising the steps of:

determining a length of detectable information conveying marking to be applied to the tissue according to the amount of medical agent desired; and

applying the determined length of marking to the tissue.

60. The method of claim 59, further comprising pre-treating the tissue prior to applying the marking.

61. The method of claim 59, further comprising applying a different marking that is detectably different from the marking.

62. The method of claim 59, wherein applying the determined length of marking comprises applying multiple drug medications to the tissue.

63. The method of claim 59, wherein the marking is applied to the tissue by a marker pen.

64. The method of claim 59, wherein the marking is applied to the tissue by a stamp device.

65. The method of claim 59, wherein the marking is applied to the tissue using thermal transfer.

66. The method of claim 59, wherein the marking is applied to the tissue using gas vapor deposition.

67. The method of claim 59, wherein the marking comprises a first color.

68. The method of claim 67, further comprising a different marking formed of a second color that is visually differentiable from the first color.

69. The method of claim 59, wherein the marking is suitable for release into a body of a patient.

70. The method of claim 59, wherein the medical ink is suitable for release into tissue of a patient.